stockrowIndivior Pharmaceuticals Inc.
SUPN Healthcare Drug Manufacturers Specialty & Generic
Indivior Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 4.29% from fiscal 2024.
- Revenue
- +13.4%
- EPS
- +241.5%
- Free cash flow
- +240.7%
- Total debt
- +51.6%
Quarter to September 2026, against a year earlier
Follow SUPN
Alert me
Indivior Pharmaceuticals Inc. (SUPN) Shares outstanding
Indivior Pharmaceuticals Inc.'s shares outstanding at the end of fiscal 2025 was $128.0M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $122.0M. Over the past ten years it has ranged from $128.0M (fiscal 2025) to $154.0M (fiscal 2020) — the current reading is the lowest in ten years. Indivior Pharmaceuticals Inc. ranks 27th of 81 Drug Manufacturers Specialty & Generic companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $128.0M | (3.76%) |
| FY2024 | $133.0M | (2.92%) |
| FY2023 | $137.0M | (1.45%) |
| FY2022 | $139.0M | (8.51%) |
| FY2021 | $151.9M | (1.34%) |
| FY2020 | $154.0M | 1.94% |
| FY2019 | $151.1M | 0.56% |
| FY2018 | $150.2M | 4.16% |
| FY2017 | $144.2M | (2.97%) |
| FY2016 | $148.6M | 1.38% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $122.0M | (1.61%) |
| Jun 2026 | $124.0M | (3.88%) |
| Mar 2026 | $129.0M | 0.78% |
| Dec 2025 | $128.0M | (0.78%) |
| 43 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| RDY Dr. Reddy's Laboratories Ltd compare | $833.3M |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | $335.7M |
| HIMS Hims & Hers Health, Inc. compare | $231.7M |
| ALKS Alkermes plc compare | $176.4M |
| SUPN Indivior Pharmaceuticals Inc. | $122.0M |
| AMLX Amylyx Pharmaceuticals, Inc. compare | $111.2M |
| LQDA Liquidia Corporation compare | $101.4M |
| KNSA Kiniksa Pharmaceuticals International, plc compare | $84.9M |
| LNTH Lantheus Holdings, Inc. compare | $68.4M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on SUPN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement